Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, PR China.
Department of colorectal surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.
Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):317-323. doi: 10.1016/j.clinre.2018.10.012. Epub 2018 Nov 15.
The aim of the present study was to compare outcomes after curative intent radiofrequency ablation and resection in patients with resectable liver metastases of Gastrointestinal Stromal Tumours (GISTs) after pre-operative tyrosine kinase inhibitor (TKI) treatment.
We retrospectively analysed data from 25 patients diagnosed with resectable liver metastases from GISTs who received pre-operative TKI treatment, who received radiofrequency ablation or resection and post-operative TKI treatment, and who were admitted to 3 institutions from January 2009 to December 2017.
Ten patients (10/25, 40.00%) underwent RFA combined with post-operative TKI treatment, and 15 (15/25, 60.00%) patients were treated with hepatic resection combined with post-operative TKI treatment. There were fewer post-operative complications (10.00% vs. 53.33%, P = 0.04) and shorter length of stay (4 vs. 9 days, P = 0.00) in the RFA group. After a median follow-up of 26 months, the 1-, 3-, and 5-year survival rates were 100.00%, 75.00%, 55.00%, respectively. The RFA group had a lower median PFS (P = 0.007, mPFS: 9 months versus 29 months), but overall survival was not influenced by the treatment modality compared with the resection group (P = 0.413, mOS: 47 months versus not reached).Hepatic resection combined with post-operative TKI treatment was the only prognostic factor for PFS in univariate analysis (HR = 0.071, 95% CI: 0.007-0.759, P = 0.029).
For patients with resectable liver metastases from GISTs after receiving pre-operative TKI treatment, compared with resection, ablation seemed to be associated with shorter progression-free survival, but RFA offered comparable overall survival, and the post- procedure morbidity and lengths of stay were significantly lower. With complete ablation of the targeted tumours, our results suggest that RFA is an acceptable option in selected patients.
本研究旨在比较术前酪氨酸激酶抑制剂(TKI)治疗后可切除胃肠道间质瘤(GIST)肝转移患者接受根治性射频消融和切除术的治疗结果。
我们回顾性分析了 2009 年 1 月至 2017 年 12 月期间,3 家医疗机构收治的 25 例接受术前 TKI 治疗后诊断为可切除肝转移 GIST 并接受射频消融或切除术联合术后 TKI 治疗的患者数据。
10 例患者(10/25,40.00%)接受 RFA 联合术后 TKI 治疗,15 例患者(15/25,60.00%)接受肝切除术联合术后 TKI 治疗。RFA 组术后并发症较少(10.00% vs. 53.33%,P=0.04),住院时间较短(4 天 vs. 9 天,P=0.00)。中位随访 26 个月后,1、3、5 年生存率分别为 100.00%、75.00%、55.00%。RFA 组中位 PFS 较低(P=0.007,mPFS:9 个月 vs. 29 个月),但与切除术组相比,总生存未受治疗方式影响(P=0.413,mOS:47 个月 vs. 未达到)。单因素分析中,肝切除术联合术后 TKI 治疗是 PFS 的唯一预后因素(HR=0.071,95%CI:0.007-0.759,P=0.029)。
对于接受术前 TKI 治疗后可切除 GIST 肝转移的患者,与切除术相比,消融术似乎与较短的无进展生存期相关,但 RFA 提供了相当的总生存期,且术后发病率和住院时间显著降低。对于目标肿瘤完全消融的患者,我们的结果表明 RFA 是一种可接受的选择。